[1]Seliger SL. Hyperkalemia in patients with chronic renal failure[J]. Nephrol Dial Transplant, 2019,34(Suppl 3): iii12-iii18.
[2]Kovesdy CP, Appel LJ, Grams ME, et al. Potassium homeostasis in health and disease: a scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension[J]. J Am Soc Hypertens, 2017, 11(12): 783-800.
[3]Nilsson E , Gasparini A , ?rnl?v, Johan, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system[J]. International Journal of Cardiology, 2017, 23(3):2825-2832.
[4] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J, 2016, 37(27):2129-2200.
[5]Hill N R , Fatoba S T , Oke J L , et al. Global Prevalence of Chronic Kidney Disease-A Systematic Review and Meta-Analysis[J]. PLOS ONE, 2016, 11(7):e0158765.
[6]Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross?sectional survey[J]. Lancet, 2012, 379 (9818): 815-822.
[7]Betts KA, Woolley JM, Mu F, et al. The prevalence of hyperkalemia in the United States[J].?Curr Med Res Opin, 2018, 34(6): 971-978.
[8]Thomsen RW, Nicolaisen SK, Hasvold P, et al. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study[J]. Nephrol Dial Transplant, 2018,33(9):1610-1620.
[9]Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries[J]. J Am Coll Cardiol, 2014, 63(12):1123-1133.
[10]Savarese G, Xu H, Trevisan M, et al. Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction[J]. JACC Heart Fail, 2019, 7(1):65-76.
[11]Thomsen RW, Nicolaisen SK, Hasvold P, et al. Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study[J]. J Am Heart Assoc, 2018, 7(11): e008912.
[12]Kashihara N, Kohsaka S, Kanda E, et al. Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan[J]. Kidney Int Rep, 2019, 4(9): 1248-1260.
[13]Torlén K, Kalantar-Zadeh K, Molnar MZ, et al. Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort[J]. Clin J Am Soc Nephrol, 2012, 7(8):1272-1284.
[14]Betts KA, Woolley JM, Mu F, et al. The Cost of Hyperkalemia in the United States[J]. Kidney Int Rep, 2017, 3(2):385-393.
[15]Epstein M, Reaven NL, Funk SE, et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors[J].?Am J Manag Care, 2015, 21(11 Suppl): S212-S220.
[16]Bushinsky DA, Rossignol P, Spiegel DM, et al. Patiromer decreases serum potassium and phosphate levels in patients on hemodialysis[J]. Am J Nephrol, 2016, 44(5): 404–410.
[17]Weir MR, Bakris GL, Pitt B. New agents for hyperkalemia[J]. N Engl J Med, 2015, 372(16):1570–1571.
[18]Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial[J]. JAMA, 2015, 314(2):151–161.
[19]Pitt B, Bakris GL, Weir MR, et al. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN[J]. ESC Heart Fail, 2018, 5(4):592–602.
[20]Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors[J]. Eur J Heart Fail, 2015, 17(10): 1057-1065.
[21]Weir MR, Bushinsky DA, Benton WW, et al. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors[J]. Am J Med, 2018, 131(5):555-564.e3.
[22]Kloner RA, Gross C, Yuan J, et al. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors[J]. J Cardiovasc Pharmacol Ther, 2018, 23(6): 524-531.
[23]Ash SR, Singh B, Lavin PT, et al. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient[J]. Kidney Int, 2015, 88(2): 404–411.
[24]Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study[J]. Clin J Am Soc Nephrol, 2019,14(6):798-809.
